Protica Bio

Operator of a bio-convergence platform intended to provide efficient ways for immunotherapy treatments.

Health Tech & Life Sciences
Active
Seed Jerusalem, Israel Founded 2021
Last updated 2026-07-26
Total raised
Last: Undisclosed Round 2022-07
Stage
Seed
Founded
2021
Headcount
3
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

Protica Bio is an Israeli startup that operates a bio-convergence platform combining proteomics and computational biology to enhance the response rate to immunotherapy, primarily immune checkpoint inhibitors in solid tumors. The company aims to identify predictive markers of response and novel drug targets for combination therapies, making cancer treatments more effective, personalized, and accessible. Their proprietary platform, developed by Prof. Tamar Geiger from the Weizmann Institute, delivers extensive protein coverage to reveal real-time biological signals that predict treatment response and uncover new therapeutic targets. Protica Bio's lead diagnostic, ProteusDx™, is designed to predict response to immunotherapy in head & neck cancer, with a pipeline indication for bladder cancer.

Funding history · 1 round · — total

2022-06
Undisclosed Round Undisclosed
★ VLX Ventures

Headcount over time

From 3 (2022-11) to 3 (2026-01) · +0 (+0%) · 12 points · source: Finder history + radar grounding
90 2022-11 2026-01

Q&A

What is Protica Bio's primary focus?
Protica Bio operates a bio-convergence platform that combines proteomics and computational biology to enhance the response rate to immunotherapy, primarily immune checkpoint inhibitors in solid tumors.
When was Protica Bio founded?
Protica Bio was founded in 2021.
What is the employee count for Protica Bio?
Protica Bio has 1-10 employees.
What is the name of Protica Bio's lead diagnostic product?
Protica Bio's lead diagnostic, ProteusDx™, is designed to predict response to immunotherapy in head & neck cancer, with a pipeline indication for bladder cancer.
Who is the CEO of Protica Bio?
Olga Nissan is the Co-Founder & CEO of Protica Bio.
What is the current funding stage of Protica Bio?
Protica Bio is currently in the Seed funding stage.
What is the primary sector of Protica Bio?
Protica Bio's primary sector is Health Tech & Life Sciences.
What technologies does Protica Bio utilize?
Protica Bio utilizes Platforms & Interfaces, Web, Artificial Intelligence, and Machine Learning technologies.

Team · 1

Olga Nissan
Founder · Co-Founder & CEO

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTest Diagnostics & Screening
Technologies
Platforms & InterfacesWebArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcareLaboratories
Business model
B2C

Tags

immunotherapypharmaceuticalsmachine-learningcancer-diagnosticstreatmentsdrug-discovery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteprotica.bio/
LinkedInlinkedin.com/company/83010471

Identifiers & details

Legal nameProtica BIO Ltd.
Founded2021
Employees (exact)3

Radar intelligence

Web history (Wayback)

Domainprotica.bio

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516511821
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2021-12-16
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2024
Active charges / liens0
Registry events2 — people (2)
Registered addressפרופ רקח 1 ירושלים

Recent registry events

DateEvent
2026-04-20עדכון דירקטורים-הסרת דירקטור
2026-04-20עדכון דירקטורים-הוספת דירקטור